trevena.com (TRVN) - Long-Term Liabilities to Capital

trevena.com - graphic logo of issuer TRVN

Trevena, Inc. (TRVN) develops advanced therapies for CNS disorders, leveraging the defensive nature of the sovereign development cycle. This price action chart, where the indicator stands at 0.00, links the production outsourcing model at Western plants with geopolitical barriers. These barriers restrict international testing and the delivery of biosamples, significantly slowing the certification of the company's new products.

Trevena Inc. (TRVN): Long-Term Debt to Equity from 07/04/2022 to 10/19/2024
Original product of Trevena Inc

This metric reflects the proportion of long-term liabilities relative to the company's equity. It measures the extent of the business's dependence on external debt financing when forming assets. Analyzing the long-term debt-to-equity coverage ratio allows for an assessment of the balance sheet structure's stability. For Trevena, Inc. (TRVN), the absence of sales revenue makes this indicator critical. Amidst a cash gap and delisting, the metric demonstrates the risk of a total loss of liquidity.

Key competitors

Long-Term Debt to Capital Ratio BIIB (Biogen Inc)|Long-Term Debt to Capital NBIX|RGC - Long-Term Liabilities to Capital|Axsome Therapeutics - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital acadia-pharm.com ACAD|XENE - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient VKTX (Viking Therapeutics Inc)|Supernus Pharma (SUPN) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Catalyst Corp (CPRX)|Long-Term Debt to Equity Ratio DNLI|HRMY (harmonybiosciences.com) - Long-Term Loans to Capital Ratio|Long-Term Debt to Equity Biohaven (BHVN)|AMLX (Amylyx Pharmaceuticals Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital TRVI (Trevi Pharma)|Praxis Corp (PRAX) - Long-Term Liabilities to Capital|AVXL: Long-Term Debt to Equity Ratio|CBLL: Long-Term Debt to Equity|PRTA: Long-Term Debt to Capital|Long-Term Liabilities to Capital Alector (ALEC)|Long-Term Debt to Equity Annexon Inc.|Long-Term Debt to Capital Ratio OMER (Omeros Corp.)|Long-Term Debt to Capital NGNE|Long-Term Debt to Capital acimmune.com (ACIU)|Voyager Therapeutics, Inc. - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient NMRA|Scilex Holding Co. - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Tevogen Bio Inc. TVGN|alphacognition.com (ACOG) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio CGTX|IKT (Inhibikase Therapeutics, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Cassava Sciences Inc (SAVA)|Long-Term Debt to Equity Ratio ASRT (Assertio Holdings, Inc.)|Ratio of Long-Term Indebtedness to Capital coyatherapeutics.com|Vistagen - Long-Term Debt to Equity Ratio|Long-Term Loans to Capital Ratio OVID (Ovid Therapeutics Inc)|ABOS - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient CRVO (CervoMed, Inc.)|ATHE (alteritytherapeutics.com) - Long-Term Debt to Equity Ratio|CLNN (Clene) - Long-Term Debt to Equity|Long-Term Debt to Equity PepGen Inc|Long-Term Debt to Capital Ratio JUNS (jupiterneurosciences.com)|Long-Term Debt to Equity Relmada Therapeutics, Inc. (RLMD)|Annovis Bio Inc - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital GRCE (Grace Therapeutics)|Firefly Neuro (AIFF) - Long-Term Liabilities to Capital|KLTO: Long-Term Debt to Equity Ratio|NRSN - Long-Term Debt to Capital|Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Long-Term Debt to Equity|MetaVia - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity NeurAxis, Inc|Long-Term Liabilities to Capital Helius Medical Technologies Inc. HSDT|Long-Term Debt to Equity Ratio PASG (Passage Bio, Inc.)|Long-Term Loans to Capital Ratio NEUP|Long-Term Debt to Equity Minerva Neurosciences, Inc. NERV|Long-Term Debt to Capital Coefficient ATHA|Addex Therapeutics, Ltd. - Long-Term Debt to Capital|Long-Term Liabilities to Capital Alzamend Neuro, Inc.|CYCN (cyclerion.com) - Long-Term Debt to Equity Ratio|PTIX (Protagenic Therapeutics, Inc.) - Long-Term Debt to Equity|KTTA (Pasithea Therapeutics Corp) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Cortigent Medical CRGT|Long-Term Debt to Equity Avenue Therapeutics, Inc (ATXI)|BrainStorm Cell Therapeutics Inc. - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital CARA (Cara Therapeutics, Inc.)|Long-Term Debt to Capital chromocell.com CHRO|ELYM: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient ITCI (Intra-Cellular Therapies)|LBPH: Long-Term Debt to Capital|MRNS - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity NKGen Biotech, Inc.|Long-Term Debt to Capital Ratio NRBO (neurobopharma.com)|Long-Term Debt to Capital SAGE|Long-Term Debt to Equity Ratio Synaptogenix Inc. SNPX|Vigil Neuroscience, Inc. - Long-Term Debt to Equity Ratio|Ratio of Long-Term Indebtedness to Capital Anew Medical Inc. (WENA)|CERE: Long-Term Debt to Equity Ratio